Valuation: Pulmatrix, Inc.

Market Cap 6.17M 5.39M 4.98M 4.59M 8.65M 594M 8.84M 59.49M 23.4M 291M 23.18M 22.67M 1B P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 2.08M 1.82M 1.68M 1.55M 2.92M 201M 2.99M 20.09M 7.9M 98.31M 7.83M 7.66M 338M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.23%
Yield 2024 *
-
Yield 2025 -
1 day+4.97%
1 week-1.74%
Current month-0.59%
1 month+12.67%
3 months+34.13%
6 months-35.62%
Current year-24.22%
1 week 1.56
Extreme 1.557
1.78
1 month 1.41
Extreme 1.4101
1.88
Current year 1.16
Extreme 1.16
3.4
1 year 1.16
Extreme 1.16
6.3
3 years 1.16
Extreme 1.16
10.4
5 years 1.16
Extreme 1.16
20.8
10 years 1.16
Extreme 1.16
1,396
Manager TitleAgeSince
Chief Executive Officer 70 20/07/2024
Director TitleAgeSince
Director/Board Member 58 01/11/2019
Director/Board Member 57 23/06/2020
Director/Board Member 55 01/10/2020
Date Insider Type Main position Quantity % Market Cap.
1/26/23 A Free

Director

1,700 0.0467%
1/26/23 A Free

Chief Financial Officer

9,900 0.2720%
1/26/23 A Free

Director

1,700 0.0467%
Change 5-day change 1-year change 3-year change Capi.($)
+4.97%-1.74%-73.30%-35.25% 6.17M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.00%-2.54%+29.36%+161.89% 23.36B
Weighted average by Cap. -2.80%-2.36%+40.12%+144.10%

Financials

2024 2025
Net sales 7.81M 6.82M 6.29M 5.8M 10.94M 752M 11.18M 75.24M 29.59M 368M 29.32M 28.67M 1.27B -
Net income -9.56M -8.35M -7.71M -7.11M -13.39M -921M -13.69M -92.14M -36.24M -451M -35.9M -35.11M -1.55B -5.16M -4.51M -4.16M -3.84M -7.23M -497M -7.39M -49.75M -19.57M -243M -19.39M -18.96M -838M
Net Debt -9.52M -8.32M -7.68M -7.08M -13.34M -917M -13.64M -91.77M -36.1M -449M -35.76M -34.97M -1.55B -4.09M -3.57M -3.3M -3.04M -5.73M -394M -5.85M -39.4M -15.5M -193M -15.35M -15.02M -664M
Logo Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
2
Date Price Change Volume
17/07/26 $1.690 +4.97% 20,753
16/07/26 $1.610 +2.55% 14,612
15/07/26 $1.570 -3.09% 11,382
14/07/26 $1.620 -2.99% 25,804
13/07/26 $1.670 -2.91% 14,797
  1. Stock Market
  2. Stocks
  3. PULM Stock